Evidence map›Paper›PMID 41872301›Full record

ArticleNature materials2026

Mechanisms of active wetting and fluidification in epithelial cell collectives.

Stefano Marchesi, Chiara Guidolin, Andrew E Massey, Gregoire Lemahieu, Zeno Lavagnino, Galina V Beznoussenko, Alexandre A Mironov, Brenda J Green, Elisa Allievi, Emanuele Martini and 19 more

Erratum issuedAbstract read
In one paragraph

Article in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Stefano MarchesiIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
Chiara GuidolinDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy.
Andrew E MasseySection on Mechanobiology, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-7688-5501
Gregoire LemahieuDepartment of Cellular Biophysics, Max Planck Institute for Medical Research, Heidelberg, Germany.ORCID 0009-0007-8647-1653
Zeno LavagninoIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-7247-8084
Galina V BeznoussenkoIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-1876-4098
Alexandre A MironovIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
Brenda J GreenIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-4274-0969
Elisa AllieviIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
Emanuele MartiniIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-3375-7726
Serena MagniIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0003-4730-9710
Andrea GhisleniIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
Caterina LomazziDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy.
Andrea Francesco BenvenutoEuropean Institute of Oncology (IEO) IRCCS, Milan, Italy.ORCID 0009-0007-9859-2188
Andreas SchertelCarl Zeiss Microscopy GmbH, Oberkochen, Germany.
Diana A van FaassenIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0009-0000-0542-9525
Stefano FreddiDepartment of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.ORCID 0000-0003-4263-3060
Giovanni BertalotEuropean Institute of Oncology (IEO) IRCCS, Milan, Italy.
Dario ParazzoliIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0001-8176-9775
Paolo MaiuriIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0001-5079-445X
Marina MapelliEuropean Institute of Oncology (IEO) IRCCS, Milan, Italy.
Salvatore PeceDepartment of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
Sara SigismundDepartment of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.ORCID 0000-0002-1396-4453
Nils C GauthierIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0003-1260-3477
Elisabetta A Cavalcanti-AdamDepartment of Cellular Biophysics, Max Planck Institute for Medical Research, Heidelberg, Germany.ORCID 0000-0003-0243-1552
Alexander X Cartagena-RiveraSection on Mechanobiology, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA. alexander.cartagena-rivera@nih.gov.ORCID 0000-0001-6227-2499
Fabio GiavazziDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy. fabio.giavazzi@unimi.it.ORCID 0000-0003-4930-0592
Giorgio ScitaIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. giorgio.scita@ifom.eu.ORCID 0000-0001-7984-1889
Andrea DisanzaIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. andrea.disanza@ifom.eu.ORCID 0000-0001-5101-2907

Funding

MechanobiologyZIAEB000094 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CARTAGENA-RIVERA, ALEXANDER · 2020 to 2025
$6.0M
Intramural NIH HHS ZIA EB000094
6 · The paper itself

Abstract

Tissue-level phase transitions are emerging as a crucial mechanism in tumour development and metastasis. When becoming invasive, epithelial tumours undergo a transition from a solid-like state to a more fluid-like one. Although the contributions of cell adhesions, traction forces and cell migration for such behaviour are known, the exact biophysical and molecular mechanisms controlling these transitions are not fully understood. Here we show that breast cancer cell fluidity is regulated by IRSp53, a protein linking plasma membranes to the cytoskeleton. In both two-dimensional monolayers and three-dimensional spheroids, the depletion of IRSp53 increases fluidity and active wetting of the substrate due to a decrease in intercellular friction and enhanced local cell rearrangements. Molecularly, IRSp53 interacts with the junctional protein Afadin to control global tensile state and active wetting, establishing these proteins as key regulators of epithelial collectives' viscosity in breast cancer tumouroids. In breast cancer patient samples, low IRSp53 expression levels and aberrant localization correlate with worse clinical outcomes. These findings support the broader relevance of IRSp53-regulated mechanics in epithelia and their potential prognostic value in cancer.

Indexed as

Breast NeoplasmsEpithelial CellsCell Line, TumorFemaleHumansMicrofilament ProteinsWettabilityMicrofilament Proteins

Identifiers

PMID41872301
PMCPMC13323089

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.